▎WuXiEdited by Kant Content Team

Today, Novo Nordisk announced in its third-quarter financial report that the pivotal therapy Ozempic (semaglutide) had reached the primary endpoint in a Phase 3b trial for treating type 2 diabetes patients with peripheral artery disease (PAD). Based on this positive result,Novo Nordisk is expected to submit a regulatory application for the expanded indication of Ozempic in the United States and the European Union in the first half of 2025.

In September 2024, Novo Nordisk successfully completed the STRIDE Phase 3b clinical trial. This was a 52-week trial comparing 1.0 mg semaglutide with placebo as an adjunct to standard care in patients with type 2 diabetes and intermittent claudication (leg muscle pain during activity) due to PAD. Analysis showed that the trial met its primary endpoint.At 52 weeks,SemaglutideAndCompared with placeboPatients significantly improved their maximum walking distance by 13%., which is clinically significant. In addition,In the semaglutide group, the maximum walking distance increased by 21% from baseline, compared to only an 8% increase in the placebo group.In the trial, the safety and tolerability of semaglutide were consistent with previous trial results.

Ozempic is a GLP-1 receptor agonist that stimulates insulin production.The once-a-week injectable form of the therapy received FDA approval in 2017.Approved for the treatment of type 2 diabetes. And in January 2020, it received FDA approval againApproval, used to reduce the risk of major adverse cardiovascular events (MACE) in adult patients with type 2 diabetes and known heart disease, such as heart attacks, strokes, or death.

In recent years,Many studies have pointed outThe main efficacy component of Ozempic, semaglutide, has the potential to treat multiple metabolism-related indications.In addition to the FDA in June 2021ApprovalIn addition to its use in treating ordinary obese patients (trade name: Wegovy), a study was published this July.Published in The Lancet's medical journaleClinicalMedicineOnResearch shows，The use of Ozempic is associated with a reduced risk of dementia and nicotine abuse.The analysis shows,Compared with DDP-4 inhibitors,Patients Treated with Ozempic Show 48% Reduced Risk of Dementia(HR=0.52, 95% CI: 0.40-0.68). In terms of nicotine abuse, patients treated with Ozempic had a 28% lower risk compared to those treated with insulin secretagogues (HR=0.72, 95% CI: 0.61-0.85). Additionally,Results from the Phase 3 FLOW clinical trial show,Ozempic can reduce the risk of major cardiovascular events by 18% and the risk of death from any cause by 20% in patients with chronic kidney disease (CKD) and type 2 diabetes.The detailed results of the trial are inMay this yearAt the same timePublishIn the top medical journal, The New England Journal of Medicine.

▲To learn more about the application of cutting-edge technologies in the biopharmaceutical industry, please long press and scan the QR code above to access "WuXi Live Studio" and watch live discussions and exciting replays on related topics.

References:

[1] Novo Nordisk's sales increased by 23% in Danish kroner and by 24% at constant exchange rates to DKK 204.7 billion in the first nine months of 2024. Retrieved November 6, 2024 from https://ml-eu.globenewswire.com/Resource/Download/74140056-5832-4a59-af10-e7defd8936b7

[2] Novo unveils new cardiometabolic data as it reports solid third-quarter profits. Retrieved November 6, 2024 from https://endpts.com/novo-unveils-new-cardiometabolic-data-as-it-reports-solid-third-quarter-profits/

Disclaimer: The content team of WuXi AppTec focuses on introducing the research progress in global biopharmaceuticals and health. This article is for information exchange only, and the views expressed in the article do not represent the position of WuXi AppTec, nor does it indicate that WuXi AppTec supports or opposes these views. This article is not a recommendation for treatment plans. For guidance on treatment options, please visit a正规 hospital.

Copyright Statement: This article is from the content team of WuXi AppTec. Individuals are welcome to share it on their social media circles, but unauthorized reproduction by media or institutions in any form to other platforms is prohibited. For authorization to reproduce, please reply with "reprint" on the WeChat Official Account of "WuXi AppTec" to obtain reprint guidelines.